Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine

Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial

(2009) C. L. Slingluff et al.   CLINICAL CANCER RESEARCH

Optimal dose and schedule of an HER-2/neu(E75) peptide vaccine to prevent breast cancer recurrence

(2008) Jarrod P. Holmes et al.   CANCER

Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

(2008) G. E. Peoples et al.   CLINICAL CANCER RESEARCH

Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission

(2008) C. S.M. Diefenbach et al.   CLINICAL CANCER RESEARCH

Therapeutic Vaccination of Chronic Hepatitis C Nonresponder Patients With the Peptide Vaccine IC41

(2008) Christoph S. Klade et al.   GASTROENTEROLOGY

Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neuPeptide (AE37) Vaccine

(2008) Jarrod P. Holmes et al.   JOURNAL OF CLINICAL ONCOLOGY

Helper T-Cell Responses and Clinical Activity of a Melanoma Vaccine With Multiple Peptides From MAGE and Melanocytic Differentiation Antigens

(2008) Craig L. Slingluff et al.   JOURNAL OF CLINICAL ONCOLOGY

A Multipeptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer

(2008) Kimberly A. Chianese-Bullock et al.   JOURNAL OF IMMUNOTHERAPY